• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NKTX

NKTX

Nkarta, Inc.

NASDAQHealthcareBiotechnologyUS

USD2.72

-0.19 (-6.53%)

Rating:C

Company Profile

CEO

Paul J. Hastings

IPO Date

2020-07-10

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.85

Prev. Close

$2.91

Day Low

$2.69

Day High

$2.85

52W Low

$1.63

52W High

$3.65

Market Cap

$0.19B

Volume

0.48M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

39.2%

Avg Negative

2.1%

Avg Neutral

58.6%

News Feed

Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site

Benzinga·7/14/2021·↑ positive

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

GlobeNewsWire·7/14/2021·↑ positive

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

GlobeNewsWire·6/14/2021
·↑ positive

How Much Will the Nkarta Deal Help CRISPR Therapeutics?

The Motley Fool·6/6/2021·↑ positive

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

GlobeNewsWire·5/13/2021·↑ positive

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

Benzinga·5/7/2021·↑ positive

NKTX Stock: Over 10% Increase Pre-Market Explanation

Pulse2·5/7/2021·↑ positive

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

GlobeNewsWire·4/28/2021·↑ positive

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

GlobeNewsWire·3/25/2021·↑ positive

Nkarta Reports Third Quarter 2020 Financial Results

GlobeNewsWire·11/12/2020·↑ positive